Cancer stem cells (H1299-sdCSCs) were obtained from tumour spheres of H1299 human lung cancer cells. We studied low stiffness, a unique biophysical property of cancer cells, in H1299-sdCSCs and parental H1299. Atomic force microscopy revealed an average Young's modulus value of 1.52 kPa for H1299-sdCSCs, which showed low stiffness compared with that of H1299 cells, with a Young's modulus value of 2.24 kPa. (−)-Epigallocatechin gallate (EGCG) reversed the average Young's modulus value of H1299-sdCSCs to that of H1299 cells. EGCG treatment inhibited tumour sphere formation and ALDH1A1 and SNAI2 (Slug) expression. AXL receptor tyrosine kinase is highly expressed in H1299-sdcScs and AXL knockdown with siAXLs significantly reduced tumour sphere formation and ALDH1A1 and SNAI2 (Slug) expression. An AXL-high population of H1299-sdCSCs was similarly reduced by treatment with EGCG and siAXLs. Transplantation of an AXL-high clone isolated from H1299 cells into SCID/Beige mice induced faster development of bigger tumour than bulk H1299 cells, whereas transplantation of the AXL-low clone yielded no tumours. Oral administration of EGCG and green tea extract (GTE) inhibited tumour growth in mice and reduced p-AXL, ALDH1A1, and SLUG in tumours.
Results
Inhibitory effects of green tea catechins on the tumour sphere formation of H1299 cells. We first confirmed that H1299 human lung cancer cells produced 35.0 ± 8.7 tumour spheres under non-attached and serum-free culture conditions. To determine the stemness properties, tumour spheres were first separated from parental H1299 cells using a filter with a pore size of more than 77 µm. Since the cells of the tumour spheres differed qualitatively from the parental H1299 cells, we named the cells H1299-sdCSC. H1299-sdCSCs had significantly increased expression of the stemness marker genes, CD133 (2.2-fold), ALDH1A1 (69.9-fold), NANOG (8.5-fold), SOX2 (19.2-fold), and OCT4 (5.0-fold), and the EMT-related genes, CDH2 (N-cadherin) (6.0-fold), VIM (Vimentin) (1.4-fold), SNAI (Snail) (4.7-fold), SNAI2 (Slug) (19.3-fold) , and ZEB1 (6.4-fold), compared with the parental H1299 ( Supplementary Fig. S1 ).
EGCG induces anticancer activity by inhibiting the expression of stemness marker genes and self-renewal of human CSCs 7 . Green tea contains at least four green tea catechins, which are divided into two groups: the cancer preventive group, which includes EGCG, (−)-epigallocatechin (EGC), and (−)-epicatechin gallate (ECG); and the inactive group, which includes (−)-epicatechin (EC) 21 . The inhibitory effects of green tea catechins on H1299-sdCSCs were investigated in a tumour sphere formation assay, using two concentrations (10 and 50 µM) of each catechin. Treatment with 50 µM EGCG, 50 µM EGC, and 50 µM ECG reduced the numbers of tumour spheres from 35.0 ± 8.7 to 16.0 ± 3.5, 27.6 ± 5.5, and 23.7 ± 2.1, respectively. Compared with the control, tumour sphere formation was reduced by 51.9%, 21.1%, and 30.7%, respectively. EC did not reduce tumour sphere formation (Fig. 1A) . Among the catechins, EGCG inhibited tumour sphere formation most effectively, and previous results support that EGCG is the most active cancer preventive compound 4 . Tumour spheres treated with EGCG were smaller than non-treated cells (Fig. 1B) . Importantly, EGCG significantly inhibited the proliferation of H1299-sdCSCs. The effects of EGCG and EC were also confirmed in another NSCLC cell line, Lu99, as shown in Supplementary Fig. S2 .
Biophysical properties of H1299-sdCSCs and their inhibition by EGCG. We previously reported the results obtained by AFM that the highly metastatic mouse melanoma variant, B16-F10, had the lowest average Young's modulus value among all melanoma variants tested 21, 22 . Thus, we believe that cell stiffness, a biophysical phenotype of cancer, is a suitable indicator of metastatic potential. To measure cell stiffness, the trypsinized H1299-sdCSCs and H1299 cells were attached to biocompatible anchor for membrane (BAM)-coated dishes 23 . AFM measurement revealed that the average Young's modulus values were 2.24 ± 0.07 kPa for H1299 and 1.52 ± 0.03 kPa for H1299-sdCSCs (Fig. 1C ). This indicated that H1299-sdCSCs possessed less stiffness and softer elasticity than H1299. Furthermore, treatment with 10 µM and 50 µM EGCG increased the average Young's modulus values of H1299-sdCSCs from 1.52 ± 0.03 kPa to 1.82 ± 0.05 kPa and 2.04 ± 0.05 kPa, respectively (Fig. 1C ). During AFM measurement, we observed that EGCG-treated H1299-sdCSCs showed a similar adherent phenotype to H1299-parental, and that suspended H1299 cells quickly adhered to BAM-coated dishes, but H1299-sdCSCs did not. We assumed that EGCG reversed the biophysical property of H1299-sdCSCs to that of H1299-parental cells, which was supported by our previous results that EGCG increased the stiffness of adhered cells in parental H1299 10 .
Inhibition of ALDH1A1 and SNAI2 (Slug) expression in H1299-sdCSCs treated with EGCG was associated with reduced ALDH-positive cells. The inhibitory effects of EGCG on the expression of five stemness marker genes and five EMT-related genes in H1299-sdCSCs were studied. Treatment with 10 µM EGCG reduced ALDH1A1 expression to 0.23 ± 0.12, and treatment with 50 µM EGCG reduced SNAI2 (Slug) expression to 0.20 ± 0.12 compared with that of H1299-sdCSCs without EGCG (Table 1) . However, EGCG did not change the expression of other stemness marker genes (CD133, NANOG, SOX2, and OCT4) or other EMT-related genes (CDH2 (N-cadherin), VIM (vimentin), SNAI1(Snail), and ZEB1 (Table 1) . Other investigators similarly reported that ALDH is highly expressed in spheroid-derived CSCs of human colorectal cancer (HCT116-SDCSCs) compared with that in parental cells, and that ALDH activity is associated with ALDH1A1 expression and high tumourigenicity 24, 25 . The percentage of ALDH-positive cells in both H1299 and H1299-sdCSCs was determined by Aldefluor flow cytometry, and we found that the proportion of ALDH-positive cells in H1299-sdCSCs were approximately 3-to 5-fold more than that in H1299 cells ( Fig. 2A ). In addition, treatment with 10 µM and 50 µM EGCG dose-dependently decreased the percentages of ALDH-positive cells in H1299-sdCSCs by approximately 0.6-and 0.4-fold, respectively ( Fig. 2A ). We confirmed that EGCG reduced ALDH1A1 protein levels in H1299-sdCSCs by immunocytochemical analysis (Fig. 2B ). The results suggest that ALDH and SLUG in H1299-sdCSCs contributed to stemness, which was inhibited by EGCG.
EGCG inhibited AXL expression in H1299-sdCSCs. AXL is a receptor tyrosine kinase. We previously reported that AXL stimulates H1299 cell softening, and treatment with the R428 AXL inhibitor reversed it 11 . As aforementioned, H1299 cells contain both high amounts of AXL protein and p-AXL at Y702. H1299 treated with 50 µM EGCG and 50 µM EGC had reduced p-AXL/AXL ratios of 0.58 and 0.64, respectively ( Supplementary  Fig. S3 ), suggesting that green tea catechins inhibited AXL activation.
We next studied the relationship between stemness and AXL protein expression in EGCG-treated H1299sd-CSCs. Flow cytometric analysis using anti-AXL antibody and AF647-labeled secondary antibody revealed that H1299-sdCSCs consisted of two populations with different AXL protein expression levels on the Contribution of AXL to H1299-sdCSC stemness. GAS6, a protein related to the anticoagulation factor protein S, is a ligand for the AXL and TAM family of receptor tyrosine kinases 14 .
To study the contribution of AXL activation to H1299-sdCSC stemness, the effect of GAS6 on tumour sphere formation was examined. Treatment of H1299 cells with GAS6 at 250 ng/ml increased p-AXL protein levels by approximately 8-fold, suggesting that GAS6 induced AXL activation ( Fig. 3A ). GAS6 treatment in the tumour sphere assay induced significantly larger spheres than those from cells without GAS6 and increased the number of tumour spheres from 100% (38.3 ± 6.5) to 146% (56.0 ± 9.5; Fig. 3A ). Importantly, activating AXL with GAS6 stimulated tumour sphere formation and stemness. We next transfected siAXL-1 and siAXL-2 into H1299 cells to reduce AXL protein levels ( Fig. 3B ). Treatment with siAXL-1 and siAXL-2 reduced the numbers of tumour spheres to 13.3% (5.3 ± 1.5) and 20.8% (8.3 ± 3.5) in the non-treated H1299 (40.0 ± 8.9), respectively, and the inhibitory effect with siAXLs was more effective than 44.3% (17.7 ± 4.0) with the siControl (Fig. 3B ). Consistent with evidence showing that EGCG reduces ALDH1A1 and SNAI2 (Slug) expression, treatment with siAXL-1 and siAXL-2 also reduced ALDH1A1 (0.78 and 0.31) and SNAI2 (Slug) (0.41 and 0.38) expression among five stemness marker genes and five EMT-related genes in H1299-sdCSCs (Table 1 ). Furthermore, H1299-sdCSCs treated with two siAXLs had a reduced percentage of ALDH-positive cells, as detected by flow cytometry, and reduced ALDH1A1 protein levels, as determined by immunocytochemistry, compared with non-treated H1299-sdCSCs ( Fig. 3C,D) . The contribution of AXL to CSCs was also confirmed in Lu99 cells and H1703-AXL cells: treatment with siAXL-1 and siAXL-2 significantly reduced the proportions of tumour spheres to 61.1% and 21.2%, respectively, in Lu99 cells ( Supplementary  Fig. S4 ). Furthermore, exogenous AXL expression stimulated tumour sphere formation in H1703 cells, which express AXL at lower levels than H1299 cells ( Supplementary Fig. S5 ). These results suggest that AXL protein stimulates ALDH1A1 and SNAI2 (Slug) expression, and increases ALDH protein and ALDH activity, suggesting that AXL is related to tumour sphere formation and stemness.
Enhanced tumourigenicity of AXL-high clones and absent tumourigenicity of AXL-low clones.
To characterize the role of AXL in tumourigenicity, we sorted 15% of the H1299 cells as the AXL-high population and 15% as the AXL-low population by flow cytometry (Fig. 4A ), and then established two cell clones: an AXL-high clone with high levels of both p-AXL and AXL, and an AXL-low clone with lower levels of both proteins. The p-AXL/ AXL ratios were 7.0-13.2 and zero for the AXL-high and AXL-low clones, respectively, and the AXL/α-tubulin ratios were 1.9-2.7 and 0.5-0.7 for the AXL-high and AXL-low clones, respectively, compared with those of the bulk H1299 cells (Fig. 4B) .
The same amounts (1 × 10 6 cells) of the two clones and the bulk H1299 cells as a control were subcutaneously transplanted into SCID/Beige mice. The AXL-high clone produced larger tumours more rapidly than the bulk H1299 cells, whereas the AXL-low clone developed no tumours at 12 injection sites in six mice by day 35 of the experiment. Importantly, all the AXL-high clones had produced tumours by day 31 (Fig. 4C ). Tumours derived from the AXL-high clone contained high levels of p-AXL and AXL compared with those from the H1299 cells ( Fig. 4D ). These results indicated that p-AXL and AXL proteins are important for high tumourigenicity.
EGCG inhibited the tumour growth of H1299 cells by reducing p-AXL, ALDH1A1, and SLUG.
Since p-AXL is an essential factor for stemness, we examined the inhibitory effect of EGCG on tumour growth in www.nature.com/scientificreports www.nature.com/scientificreports/ H1299 cells in vivo using a mouse xenograft model. EGCG (100 mg/kg) and 0.2% GTE were administered from one day before injection of H1299 (10 6 cells/injection) to the end of the experiment. The total amount of green tea catechins per day/mouse was estimated as 4.4 mg/mouse, the equivalent of 10 cups of green tea/day, which is the cancer preventive amount for humans [1] [2] [3] [4] . The group treated with EGCG + GTE showed delayed tumour development (Fig. 5A) ; tumours were found in 75% (9/12) of the injected sites of the EGCG + GTE group, whereas tumours of the non-treated group developed in 100% (12/12) of the injected sites at 35 days after injection (Fig. 5B) . The tumour size of the EGCG + GTE group was relatively smaller than that of the non-treated group (Fig. 5B) , and the average tumour weight of the EGCG + GTE group was 0.05 ± 0.06 g, which was significantly lower than that of the non-treated group (0.10 ± 0.06 g; Fig. 5C ). Notably, tumours of the EGCG + GTE group had lower levels of p-AXL and AXL compared with those of the non-treated group. In addition, EGCG + GTE inhibited AXL activation in tumours (Fig. 5D ), which possessed lower levels of ALDH1A1 and SLUG proteins than those of the non-treated group (Fig. 5D ). The p-AXL levels were well correlated with the ALDH1A1 and SLUG levels in the tumours, with r values of 0.87 and 0.65 (Fig. 5E ). Thus, we concluded that the ALDH1A1 and SLUG axis regulated by AXL is involved in tumourigenicity and stemness, and that cancer prevention with EGCG mediates inhibition of the AXL/ALDH/SLUG axis.
Discussion
Here we report for the first time the biophysical properties of H1299-sdCSC human lung cancer stem cells. AFM revealed that the average Young's modulus value for H1299-sdCSCs was 1.52 kPa, which was 0.68-fold lower than that for the parental H1299 at 2.24 kPa. A previous investigation using AFM reported a 0.7-fold lower stiffness in a human hepatoma stem cell line, MHCC97H, compared with that of the parental cells 26 . Other researchers using a microfluidic device reported a higher deformability in ALDH + CSCs isolated from an inflammatory breast cancer cell line, SUM149, than that in ALDH − cells 27 . Cross et al. first reported that the average Young's modulus value for metastatic cancer cells isolated from the pleural fluid of lung, breast, and pancreatic cancer patients tended to be approximately 0.33-fold lower than that of normal mesothelial cells 8 . We think that low stiffness, soft elasticity, high deformability, and metastatic potential are unique biophysical properties of CSCs isolated OCT4, NANOG, and SOX2 are transcription factors that are required to maintain pluripotency 30 . Sphere-derived CSCs of colorectal cancer (HCT116-SDCSCs) express significantly higher levels of stemness marker genes, for example, 4.5-fold higher levels of OCT4 and 3.2-fold higher levels of NANOG compared with those of the parental cells 25 . We also found that H1299-sdCSCs expressed OCT4, NANOG, and SOX2 genes at levels of 5-fold more than the parental H1299 cells. Our study revealed that EGCG inhibited ALDH1A1 and SNAI2 (Slug) expression and ALDH activity, but not OCT4, NANOG, or SOX2 expression. Other investigators reported that EGCG inhibited the mRNA and protein expression of stemness markers, including OCT4 and NANOG, and increased the apoptotic markers BAX and caspase-8 in 20 human CSC lines collected from nine different cancer tissues 7 . But EGCG selectively inhibits ALDH and SLUG in this study. Some investigators reported that ALDH acts as a critical factor for cancer stemness 31 , and that SLUG promotes the expansion of CSCs in NSCLC by interacting with SOX9 32 . However, the mechanism of ALDH and SLUG has not yet been elucidated. www.nature.com/scientificreports www.nature.com/scientificreports/ AXL is reported to induce EMT and self-renewal in breast cancer cells and chronic myelogenous leukemia CSCs 18, 19 , and has a crucial role in the CSCs of various cancers. Kinome-wide shRNA screening revealed AXL to be an upregulated and phosphorylated receptor tyrosine kinase (RTK) amongst 82 RTKs in mesenchymal glioma stem-like cells 20 . Highly phosphorylated AXL is often found in NSCLC tissues and cell lines, but AXL is not expressed in normal lung tissues. Flow cytometry analysis revealed the presence of two populations with different AXL protein levels in H1299-sdCSCs, and the AXL-high and AXL-low clones showed different tumourigenicities. Importantly, AXL-high clones contained 3.5-6.1-fold higher p-AXL protein levels than AXL-low clones, and the AXL-low clone did not contain p-AXL, indicating the essential contribution of p-AXL to tumourigenicity. Our results are well supported by evidence that the p-AXL levels in tumours of the EGCG + GTE group were strongly reduced by 0.36-fold compared with those of the non-treated group, whereas AXL levels in tumours from both groups were nearly the same. These results clearly indicate that tumourigenicity and stemness require AXL activation with high p-AXL levels.
AXL activation is both GAS6-dependent and -independent 14 . Because AXL interacts with cMET, EGF receptor (EGFR), and human EGFR-related 2 (HER2), AXL-RTK crosstalk induces the transactivation of AXL in lung and breast cancers 16, 33, 34 . AXL expression was positively associated with GAS6 expression, and high coexpression of AXL/GAS6 was a strong risk factor in one study population 35 . EGCG treatment reduced AXL phosphorylation in the absence and presence of GAS6 ( Supplementary Fig. S3A,B) , indicating that EGCG inhibits AXL activation in both a GAS6-dependent and -independent manner. We previously reported that EGCG altered membrane organization to rigid stiffness, which we termed the "sealing effect of EGCG" 21 . Matsuzaki et al. recently found that treatment with the giant liposome of EGCG increased the stiffened bending rigidity of the lipid membrane by approximately 60 times more than that without EGCG 36 . Because altering the membrane organization with EGCG inhibits EGFR activation, EGCG likely inhibits AXL transactivation via AXL/RTK crosstalk.
AXL acts as a driver for acquiring chemoresistance against tyrosine kinase inhibitors (TKIs) and conventional anticancer drugs. Zhang et al. reported that activating AXL caused resistance to EGFR-targeted TKIs such as erlotinib in lung cancer, and that genetic and pharmacological inhibition of AXL restored TKI sensitivity 16 . Therefore, AXL inhibitors are attracting attention to overcome chemosensitivity, and clinical studies of several specific AXL Numbers indicate fold levels of p-AXL/ AXL and AXL/α-tubulin compared with those of bulk H1299 cells. Full-length blots/gels are presented in Supplementary Information WB-3. (C) Tumour incidences and tumour volume in the AXL-high clone (•), bulk H1299 cells (▴), and the AXL-low clone (○). The same number of cells (1 × 10 6 ) were subcutaneously transplanted into the backs of SCID/Beige mice. Tumour volume was calculated as described in the Materials and Methods. The image shows the mice in all three groups at 35 days after transplantation. (D) p-AXL and AXL levels in tumours of AXL-high clone and bulk H1299 cells. p-AXL, AXL, and α-tubulin (control) protein levels in tumours were examined by western blotting. Full-length blots/gels are presented in Supplementary Information WB-4. Tumour samples for western blotting were derived from the same experiment and gels/blots were generated in parallel and conducted three times.
inhibitors are underway 17 . EGCG reversed cisplatin resistance by downregulating AXL and TYRO3 expression in NSCLC and sensitizing 5-FU-resistant colorectal cancer 37 . These results suggest that the combined effects of EGCG and other compounds inhibit stemness through the AXL axis.
Protein tyrosine phosphatase 4 A (PTP4A) is a member of the phosphatase of regenerating liver (PRL) family, and PRLs are oncogenic across many human cancers 38 . Here, we discussed the results of AXL activation; however, PTP4A in human cancers should be considered in future studies.
In conclusion, AXL regulates the biophysical properties of CSCs, including low stiffness and soft elasticity. Stiffening CSCs via AXL inhibition is a critical mechanism of the multiple benefits provided by EGCG, including preventing cancer, inhibiting metastasis, and overcoming chemoresistance.
Methods
cell cultures and reagents. The human NSCLC cell line, H1299 (ATCC CRL-5803), was purchased from American Type Culture Collection (ATCC; Manassas, VA, USA) and cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum (Nichirei Bioscience Inc., Tokyo, Japan). The cells, which were confirmed as mycoplasma-free, were used at less than 20 passages and authenticated by short-tandem repeat profiling conducted by ATCC. EGCG of >98% purity was isolated from Japanese green tea leaves, and GTE was kindly provided by Dr. Atsuhi Takahashi at Saitama Tea Institute, as described previously 1, 10 . Anti-AXL (R&D Systems, Minneapolis, MN, USA), anti-p-AXL (Y702) (Cell Signaling Technology, Inc., Danvers, MA, USA), anti-SLUG (Cell Signaling Technology, Inc.), anti-ALDH1A1 (Santa Cruz, Biotechnology, Inc., Santa Cruz, CA, USA), and anti-α-tubulin (Cell Signaling Technology, Inc.) antibodies were used for the experiments. Western blot analysis. Cells or tumours were lysed in strong lysis buffer containing 20 mM Tris-HCl at pH 8.0, 150 mM sodium chloride, 1% Triton X-100, 0.1% sodium dodecyl sulfate (SDS), 1% sodium deoxycholate, 10 µg/ml aprotinin, 10 µg/ml leupeptin, 1 mM phenylmethylsulfonyl fluoride, 1 mM sodium orthovanadate, 0.5 mM sodium pyrophosphate, and 5 mM sodium fluoride, as described previously 11 . The lysates were subjected to SDS-PAGE, and then transferred onto a nitrocellulose membrane. The membrane was then incubated with primary antibody overnight at 8 °C, then incubated with the appropriate horseradish peroxidase-conjugated secondary antibody against rabbit IgG or mouse IgG. Specific bands were then detected using ImmunoStar LD (Wako Pure Chem. Ind. Ltd., Tokyo, Japan) using the C-DiGit Chemiluminescent Western Blot Scanner (LI-COR Bioscience Inc., Lincoln, NE, USA) or the LAS 4000 IR multi-color (Fujifilm Co, Tokyo, Japan). Band intensity was measured using C-DiGit or ImageJ (National Institute of Health, Bethesda, MD, USA). α-Tubulin was used as an internal control. At least three independent experiments were conducted.
Quantitative real-time RT-PCR (qRT-PCR).
Total RNA isolated from the spheres was reverse transcribed into cDNA using oligo(dT) 16 and MuLV reverse transcriptase (Thermo Fisher Scientific), and real-time PCR was conducted using SYBR Green I (LightCycler 480, Roche Lifescience, Basel, Switzerland) as described previously 40 . The primers used are indicated in Supplementary Table S2 . GAPDH was used as an internal control, and relative gene expression was calculated as the fold expression compared with that of the control tumour spheres or H1299-parental cells. At least three independent experiments were conducted.
Flow cytometry analysis of AXL. AXL protein level was examined via flow cytometry after incubation with anti-AXL antibody. Briefly, tumour spheres were treated with 0.1% trypsin and 0.02% EDTA solution containing 200 U/ml DNase I and 5 mM MgCl 2 for 3 min at 37 °C. Separated sphere-derived cells were incubated with anti-AXL antibody for 30 min on ice, washed, and further incubated with AlexaFluor647-conjugated anti-goat IgG antibody (Invitrogen, Waltham, MA, USA) for 30 min on ice. Fluorescence intensity was determined via flow cytometry (BD FACSCanto II, BD Bioscience, San Jose, CA, USA) 40 . The experiments were independently conducted three times. Fifteen percent of both the AXL-high and AXL-low populations from H1299 cells were sorted using the BD FACS AriaIII (BD Bioscience) and cloned by seeding a single cell into a 96-well plate to obtain AXL-high and AXL-low clones.
Aldefluor assay. ALDH activity was detected using the Aldefluor assay kit (StemCell Technologies, NC, USA) per the manufacturer's instructions. Separated sphere-derived cells were incubated with BODIPY-aminoacetaldehyde (BAAA) for 30 min at 37 °C. Cells that catalysed BAAA to BODIPY-aminoacetate were analysed by flow cytometry (BD FACSCanto II, BD Bioscience) to determine ALDH-positive cells. The baseline of fluorescence was determined using the ALDH inhibitor, N,N-diethylaminobenzaldehyde (DEAB) 24 . The percentage of ALDH-positive cells was analysed using FlowJo software (FlowJo, LLC, Ashland, OR, USA). The results are expressed as the means of three independent experiments ± SD.
immunocytochemistry. Tumour spheres were fixed with 4% paraformaldehyde containing 0.2% Triton X-100 for 20 min and then incubated with 25% BlockAce (KAC Co. Ltd, Tokyo Japan) for 10 min. Anti-ALDH1A1 antibody (×500 dilution in BlockAce) was used as the first antibody and AF488-labeled anti-mouse IgG was used as the second antibody. Stained spheres were observed with a fluorescent microscope (BIOREVO BZ-9000, Keyence, Osaka, Japan). The average fluorescent intensity was obtained by BZ-X Analysis Application (Keyence).
Tumour xenograft experiments. AXL-high or AXL-low clones (1 × 10 6 cells/100 µl saline) were injected at two sites of the subcutaneous flanks of six 5-week-old female SCID/Beige mice. Tumour growth was monitored for 35 days by taking caliper measurements of the tumour size. Tumour volume was calculated by the formula, width 2 × length/2 11 . EGCG (100 mg/kg) was orally administered using an intubation tube, and 0.2% GTE solution
